This cluster randomised trial will examine the impact of introducing TyphiBEV, a typhoid conjugate vaccine licensed in India, on the incidence of typhoid fever in a high burden urban setting in South India.
Who can participate
Age range1 Year – 30 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Consent
* For adults, 18 years and over - they must be willing and competent to provide informed consent
* For those aged under 18 years, the parent/guardian is willing and competent to provide informed consent, and if the participant is 11 to 18 years of age, informed assent will also be sought,
* Age:
* Between 1 and 30 years (i.e., up to 29 years 364 days) at time of recruitment into the surveillance
* Currently living within the study catchment area with no plans to leave the study area in the next 24 months
Exclusion Criteria:
* For fever surveillance
o Medical reasons that prevent the participant from complying with study requirements including follow up and testing during illness
* For vaccination
* Has received a typhoid vaccine in the previous three years
* Is known to have an allergy to any vaccine component
* Nursing mothers, Pregnancy or planning pregnancy around vaccination
* Receipt of any other vaccine in the past 30 days (temporary exclusion)
* Febrile illness in the 24 hours before vaccination (temporary exclusion)
What they're measuring
1
Total effect
Timeframe: at 24 months of follow up beginning 28 days after vaccine introduction in vaccine clusters.